Ana Plana

Ana Plana at Cleveland Clinic contributes to understanding the cardiovascular consequences of emerging cancer immunotherapies — particularly the cardiac effects of cytokine release syndrome (CRS) in CAR-T cell therapy and the management of hemodynamic compromise in severe CRS. As novel immunotherapies generate new cardiac toxicity patterns, her work on characterizing and managing these emerging complications is increasingly relevant.